Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Sancho Martín, Francisco Javier 
dc.contributor.authorSánchez García, Ana María de los Ángeles 
dc.contributor.authorVega Castrillo, Aurelio 
dc.contributor.authorNoriega González, David César 
dc.contributor.authorNocito Colón, Mercedes
dc.date.accessioned2018-11-08T09:47:55Z
dc.date.available2018-11-08T09:47:55Z
dc.date.issued2017
dc.identifier.citationTransplantation Direct, 2017 - Volume 3 - Issue 9 - p e205es
dc.identifier.issn2373-8731es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/32543
dc.descriptionProducción Científicaes
dc.description.abstractThe necessity for more effective therapies for chronic osteoarticular diseases has led to the development of treatments based on mesenchymal stem cells (MSCs), the natural precursors of musculoskeletal tissue. Treatments with autologous MSCs yielded excellent results, with nearly 70% improvement of pain and disability in osteoarthritis and degenerative disc disease. Using allogeneic MSCs is logistically more convenient and would widen the pool of eligible patients, but potential immune rejection should be considered. In this context, MSCs are purportedly immune evasive and better tolerated than other cell types. Methods We used samples collected during the performance of 2 randomized clinical trials using allogeneic bone marrow MSCs for treatment of osteoarthritis (NCT01586312) and degenerative disc disease (NCT01860417). Serum samples were used to determine anti-HLA antibodies, whereas either blood or MSC samples were used for HLA typing of recipients and donors, respectively. Algofunctional indexes were used as indicators of clinical evolution, and the correlation between the number of donor-host HLA mismatches and the efficacy of treatment was determined. Results Immune response was weak and transient, with reactivity decaying during the first year. Consistently, better donor-recipient HLA matching did not enhance efficacy. Conclusions This lack of reactivity is presumably due to the cooperation of 2 factors, (1) downregulation of the host immune responses by the transplanted MSCs and (2) effective insulation of these cells inside the articular cavity or the intervertebral disc, respectively. Interestingly, better HLA matching did not enhance efficacy. These observations have medical relevance as they support the clinical use of allogeneic cells, at least as a single-dose administration. Multiple-dose applications will require further research to exclude possible sensitization.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherLippincott, Williams & Wilkinses
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.classificationHLAes
dc.subject.classificationAntígeno leucocitario humanoes
dc.subject.classificationHuman leukocyte antigenes
dc.titleInfluence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Diseasees
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doihttps://doi.org/10.1097/TXD.0000000000000724es
dc.relation.publisherversionwww.transplantationdirect.comes
dc.peerreviewedSIes
dc.description.projectRed de Terapia Celular of the Instituto de Salud Carlos III (RD16/0011/0003) and Centro en Red de Medicina Regenerativa de Castilla y Leónes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem